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Abstract
Background: Adrenal hypoplasia is a rare congenital disorder, which can be classified into a non-syndromic form,
without extra-adrenal features, and a syndromic form, with such features. Despite biochemical and molecular genetic
evaluation, etiologic diagnosis cannot be performed in many patients with adrenal hypoplasia.
Case presentation: The patient in this case was a boy born at 31 weeks of gestation with a weight of 882 g (< 3rd
percentile) to non-consanguineous parents. Genital examination showed micropenis and bilateral cryptorchidism. On
the third day of life, he manifested hypotension with high urine output, hyponatremia, hyperkalemia, hypernatriuria,
high plasma adrenocorticotropic hormone level, and high plasma renin activity, suggesting acute adrenal insufficiency.
The serum 17α-hydroxyprogesterone level was normal. Adrenal insufficiency improved following administration of
hydrocortisone and 9α-fludrocortisone, but the patient died of recurrent infection at 4 months of age. He was suspected
as IMAGE (Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal hypoplasia congenita, and Genital anomalies)
syndrome. However, no mutation in CDKN1C was identified. Targeted exome sequencing using the TruSight One
Sequencing Panel (Illumina) identified a heterozygous mutation of c.2944C > T (p.R982C) in exon 3 in SAMD9.
Conclusion: This report describes the first Korean case of MIRAGE syndrome. The patient presented with severe primary
adrenal insufficiency, intrauterine growth retardation, and recurrent infection. SAMD9 mutation should be considered in
patients who present with adrenal hypoplasia and extra-adrenal phenotypes.
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Background
Major etiologies of adrenal insufficiency in children
include impaired steroidogenesis, adrenal hypoplasia,
familial glucocorticoid deficiency (FGD), FGD-like disor-
ders, and adrenal destruction [1, 2]. Congenital adrenal
hyperplasia accounts for 80% of the causes of pediatric
adrenal insufficiency [1]. Recent advances in molecular
genetic technologies have enabled identification of a var-
iety of rare causative genes in patients with primary ad-
renal insufficiency [2, 3]. However, 20%–60% of patients
with primary adrenal insufficiency remain genetically
undiagnosed [2, 4]. Causative genes for primary adrenal
hypoplasia include NR0B1 and NR5A1, which play a key
role in human adrenal development [5, 6], and
CDKN1C, which is known to cause IMAGE (Intrauter-
ine growth restriction, Metaphyseal dysplasia, Adrenal
hypoplasia congenita, and Genital anomalies) syndrome
[7, 8]. Mutations in MC2R, MRAP, NNT, TXNRD2, and
AAAS are related to adrenal hypoplasia as part of an
adrenocorticotropic hormone (ACTH) resistance syn-
drome [1]. Adrenal hypoplasia occurs secondarily to de-
fects in transcription factors involved in pituitary
development, such as HESX1, LHX4, and SOX3 [9], and
rare syndromes such as Meckel-Gruber syndrome, Pena-
Shokeir syndrome, hydrolethalus syndrome, Galloway-
Mowat syndrome, and Pallister-Hall syndrome [3].
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In 2016, mutations in SAMD9 were identified in patients
with adrenal hypoplasia with extra-adrenal features such
as intrauterine growth restriction, recurrent infections,
gonadal and bone marrow failure, a condition designated
as MIRAGE (Myelodysplasia, Infection, Restriction of
growth, Adrenal hypoplasia, Genital phenotypes, and En-
teropathy) syndrome [10]. To date, a total of 21 patients
with the syndrome, with 16 different mutations, have been
reported [10–12].
It is difficult to make a correct diagnosis in patients
with syndromic adrenal hypoplasia owing to the diverse
genetic etiologies and overlapping clinical and biochem-
ical features. The present report describes a patient with
MIRAGE syndrome who presented with intrauterine
growth retardation, adrenal insufficiency, and recurrent
infection and had been initially suspected as having
IMAGE syndrome.
Case presentation
The patient in this case was the first child born to non-
consanguineous parents with no family history of ad-
renal insufficiency. He was born at 31 weeks of gestation
by Cesarean section, owing to severe oligohydramnios
and fetal heart rate variability. At birth, the patient had
symmetric intrauterine growth retardation with a weight
of 882 g (< 3rd percentile), a length of 35 cm (< 3rd per-
centile), and a head circumference of 24 cm (< 3rd
percentile). On physical examination, profound skin
hyperpigmentation, frontal bossing, low-set ears, bilat-
eral cryptorchidism, and micropenis were noted.
The patient underwent mechanical ventilation immedi-
ately after birth owing to respiratory difficulty. Indometh-
acin was used on the sixth day of life to treat patent
ductus arteriosus with pulmonary edema, and closure was
eventually achieved. Three days after birth, the patient
manifested hypotension, polyuria (8.1 mL/kg/h), hypona-
tremia (128 mmol/L), hyperkalemia (6.0 mmol/L), hyper-
natriuria (104 mEq/L), and an increased fractional
excretion of sodium (6.2%). Plasma ACTH level was
tremendously elevated to 4670 pg/mL (normal range, 10–
60 pg/mL), with plasma cortisol at 5.6 μg/dL (normal
range, 2.5–9.1 μg/dL), plasma renin activity at 217 ng/mL/
h (normal range, < 2.8 ng/mL/h), and plasma aldosterone
at 55.1 pg/mL (normal range 190–1410 pg/mL), sug-
gesting severe adrenal crisis. However, plasma 17α-
hydroxyprogesterone level was 6.0 ng/mL (normal
range at gestational age of 31 weeks, 1–172 ng/mL).
A stress dose of intravenous hydrocortisone (95 mg/
M2/day), fludrocortisone acetate (0.02 mg/day), and
sodium chloride (8 mEq/kg/day) were administered.
Subsequently, the patient’s serum electrolytes, ACTH
level, and blood pressure normalized, and the skin
hyperpigmentation also showed improvement. The plasma
ACTH level decreased to 82.7 pg/mL after 1 week of
therapy and was maintained between 20 pg/mL and 40 pg/
mL during the follow-up period. Abdominal ultrasonog-
raphy revealed non-visualization of both adrenal glands
and the right testis. The left testis was located in the pa-
tient’s abdominal cavity, and a right inguinal hernia was ob-
served. Brain ultrasonography was normal.
Mild thrombocytopenia, ranging from 70,000 to
150,000/mm3, and normocytic anemia, ranging from 6.4
to 10.8 g/dL, manifested during the first week of life.
Thrombocytopenia and anemia resolved spontaneously
1 month after birth, with the counts maintained over
300,000/mm3 and 10 g/dL, respectively. Blood cultures
were negative for bacteria, and there was no evidence of
congenital infections including toxoplasmosis, rubella,
cytomegalovirus (CMV), or herpes simplex virus. Serum
IgM level was below 4.5 mg/dL (normal range, 7.3 ±
3.3 mg/dL). The thymic shadow was visible on chest
radiography. At 1 month of age, an elevation in C-
reactive protein (CRP) up to 3 mg/dL and leukocytosis
(white blood cell [WBC] count of 35,400/mm3) were ob-
served. Intravenous antibiotics, including vancomycin
and amikacin, were administered under the diagnosis of
neonatal sepsis. Serratia marcescens (S. marcescens)
(50,000/mL) and Enterococcus faecium (> 100,000/mL)
were cultured in urine. However, no bacteria were iso-
lated in blood cultures or cerebrospinal fluid. Follow-up
urine culture was clear after administration of antibiotics
for 4 days; however, CRP and WBC count were still ele-
vated to 2–3 mg/dL and 15,000–20,000/mm3, respect-
ively. Two weeks later, the patient manifested apnea and
decreased oxygen saturation, with diffuse haziness in
both lungs on chest radiography. Despite administration
of antibiotics including vancomycin, imipenem/cilasta-
tin, and amphotericin B, pneumonia, and respiratory
difficulty gradually worsened, ultimately requiring the
resumption of mechanical ventilation. Urine CMV cul-
ture, blood CMV polymerase chain reaction, and blood
CMV IgG and IgM tests were all positive. Blood and
urine CMV cultures were converted to negative after
3 weeks of intravenous ganciclovir. After 3 weeks of
mechanical ventilation, S. marcescens was identified from
cultured endotracheal aspirates (100,000,000/mL) and
urine (80,000/mL). Despite antibiotic treatment, pneumo-
nia was aggravated, and S. marcescens was also identified
in blood cultures when the patient was 4 months old. CRP
and WBC count rose to 25.9 mg/dL and 32,100/mm3, re-
spectively. The pneumonia and sepsis exacerbated and the
patient died of septic shock at 4 months of age.
The patient’s karyotype performed at age one month was
46, XY without any chromosomal structural abnormality.
Under suspicion of X-linked adrenal hypoplasia congenita
or IMAGE syndrome, genetic analysis was performed.
However, no mutation was identified in the NR0B1 or
CDKN1C genes by Sanger sequencing. Therefore, targeted
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exome sequencing was performed using genomic DNA ex-
tracted from peripheral blood leukocytes. Written informed
consent was obtained for exome sequencing from all par-
ents and the study was approved by the local ethics com-
mittee. The exome was captured using the Trusight One
Panel (Illumina Inc., San Diego, CA, USA), which enriches
a 12-Mb region spanning 4813 genes, and was sequenced
on the NextSeq platform (Illumina Inc.). The mean depth
of coverage was 114× and approximately 98% of targeted
bases were read more than 10×. Reads were aligned to the
hg19 human reference genome. The result was identifica-
tion of a heterozygous missense variant of c.2944C >T
(p.R982C) in exon 3 in the SAMD9 gene, which was re-
ported to be pathogenic with gain-of-function effect [11]
(Fig. 1). This variant was not found in normative population
databases including 1000Genomes browser (http://pha-
se3browser.1000genomes.org/) and Exome Aggregation
Consortium Browser (http://exac.broadinstitute.org/) and
predicted to be damaging by in silico prediction programs,
including PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/; score of 0.616) and Sorting Intolerant From Toler-
ant (http://sift.jcvi.org/; score of 0). This mutation was con-
firmed by Sanger sequencing using custom-designed
primers (Fig. 2). Genetic analysis of parents could not be
performed to confirm the de novo nature of the variant be-
cause the parents’ blood samples were not available.
Discussion and conclusions
This report describes a case of MIRAGE syndrome with
a heterozygous missense mutation in SAMD9 in a pa-
tient who was initially suspected as having IMAGE
syndrome. Recent advances in molecular genetic tech-
nologies have enabled the identification of new causative
genes in patients with primary adrenal insufficiency of
unknown etiology, but some patients remain genetically
undiagnosed. To avoid missing the diagnosis of this
newly recognized disease, it is necessary to carefully
examine the extra-adrenal features.
Common features of MIRAGE syndrome include re-
current invasive infection, restriction of growth, adrenal
hypoplasia, and genital phenotypes [10, 11]. Other
clinical features are preterm delivery, respiratory distress
syndrome, and frontal bossing [11]. Chronic diarrhea
with colonic dilatation was observed in almost all pa-
tients in previous reports [10, 11]. Clinical characteristics
of patients with MIRAGE syndrome in previous studies
and the present report are summarized in Table 1. In the
case described here, the patient manifested no gastro-
intestinal symptoms or additional features such as cere-
bellar hypoplasia, hydrocephalus, or short phalanges.
Myelodysplastic syndrome with mosaic monosomy 7
or monosomy 7q by the loss of the other allele on
chromosome 7 has been founded in as many as seven of
19 patients, suggesting a gain of survival advantage [10, 11].
Secondary somatic loss-of-function mutations of SAMD9
have been identified in four of eight patients, and this type
of mutation also seems to be part of a survival strategy [11].
More than half of the identified patients died before 2 years
of age owing to invasive infection including sepsis, meningi-
tis, and fungal infections [10, 11]. Postmortem analysis of
two patients revealed thymic hypoplasia with a decrease in
the number of cortical lymphocytes [10]. Two patients with
mosaic monosomy 7 or monosomy 7q who underwent
bone marrow transplantation were alive at the time of the
report [11]. Discovering the pathogenesis of recurrent
invasive infection in patients with MIRAGE syndrome
might help increase survival, considering that almost
all patients in the studies to date have died as a re-
sult of infection [10, 11].
SAMD9 protein products are involved in the endo-
some system and might influence the growth factor sig-
nal transduction pathway [10, 13, 14], resulting in
profound growth inhibition in in vitro analysis [10, 11].
SAMD9 protein products contain a sterile alpha motif
(SAM) domain near the N-terminal region and a widely
expressed putative protein interaction module involved
in interactions with proteins, DNA, and RNA. [13, 15].
Several phenotypes of SAMD9 disorders seem to be
causally related to the wide expression of the SAMD9
gene, including its expression in adrenal glands, colon,
bone marrow, liver, immune system, lung, and testis
[11, 16]. Biallelic inactivating mutations in SAMD9
Fig. 1 Mutation spectrum of SAMD9 gene in patients with MIRAGE syndrome. *, a mutation in the current study
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cause normophosphatemic familial tumoral calcinosis,
leading to the hereditary form of dystrophic calcifica-
tion in the skin [13, 17, 18]. Downregulation of
SAMD9 has also been found in mouse models with
aggressive fibromatosis, breast cancer, colon cancer,
and non-small cell lung cancer [15, 19]. In contrast,
overexpressing SAMD9 mutations are presumed to be
related to growth-restricting conditions due to the
gain of function [10, 11].
The differential diagnosis of congenital adrenal hypo-
plasia includes X-linked adrenal hypoplasia congenita,
NR5A1 mutation, Xp21 contiguous gene deletion syn-
drome, IMAGE syndrome, and ACTH insensitivity syn-
drome [1, 3]. Even within the same disease, the degree
of clinical manifestations varies widely. Extra-adrenal
features must be evaluated carefully to perform a diag-
nosis in patients with syndromic adrenal hypoplasia.
IMAGE syndrome and MIRAGE syndrome share com-
mon features such as intrauterine growth restriction, ad-
renal hypoplasia, and genital anomalies, which could
lead to confusion in diagnosis. Other characteristic fea-
tures of IMAGE syndrome such as metaphyseal dyspla-
sia, relative macrocephaly, and hypercalciuria have not
been reported in MIRAGE syndrome [7]. The presence
of recurrent invasive infection or chronic diarrhea sug-
gests MIRAGE syndrome [10, 11].
In conclusion, SAMD9 mutation should be considered
in patients who present with adrenal hypoplasia and
extra-adrenal phenotypes such as intrauterine growth re-
striction and recurrent infection. Further research is ne-
cessary to investigate this extremely rare cause of primary
adrenal insufficiency with extra-adrenal features.
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Table 1 Clinical characteristics of patients reported to have SAMD9










Male:Female 7:4 8:0 Male
IUGR 11 8 +










Recurrent infection 10 7 +





Survival 3 2 –
IUGR intrauterine growth restriction, NA not assessed
Fig. 2 Partial sequence of the SAMD9 gene. Sanger sequencing of SAMD9 identified a heterozygous mutation of c.2944C > T (p.R982C) in exon 3
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